Citius Pharmaceuticals, Inc.
Corporate Presentation
Winter 2020-21
NASDAQ: CTXR
Disclaimer
This presentation has been prepared by Citius Pharmaceuticals, Inc. (the "Company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the Company or any director, employee, agent, or adviser of the Company. This presentation does not purport to be all-inclusive or to contain all of the information you may desire. The information contained in this presentation and the comments and remarks of the representatives of the Company made during any presentation to which this presentation relates are integrally related and, as such, are intended to be delivered and understood together. Information provided in this presentation speaks only as of the date hereof. The Company assumes no obligation to update any statement after the date of this presentation as a result of new information, subsequent events or any other circumstances.
This presentation also includes express and implied forward-looking statements regarding the current expectations, estimates, opinions and beliefs of the Company that are not historical facts. Such forward-looking statements may be identified by words
such as "believes", "expects", "endeavors", "anticipates", "intends", "plans", "estimates", "projects", "should", "objective" and variations of such words and similar words. The accuracy of such statements is dependent upon future events, and involves known and unknown risks, uncertainties and other factors beyond the Company's control that may cause actual results to differ materially from what is presented herein. Investors are strongly encouraged to carefully review the Company's SEC filings for a listing of the risks that could cause actual results to differ from these forward looking statements. These forward-looking
statements speak only as of the date of this presentation and should not be construed as statements of facts.
NASDAQ: CTXR | 2 |
Company Overview
Four Active | Mino-Lok in late Phase 3; favorable review received for Futility | |
Programs with a | Analysis by Data Monitoring Committee (12/2019); favorable review | |
Late Stage Lead | for safety and efficacy analysis in September (2020). | |
Asset |
Large Market | CRBSI market estimated to be >$1.8 B worldwide; ARDS market large | |
Needs | with no approved therapies; TE infection prevention estimated at | |
>$0.4 B worldwide; Rx hemorrhoid market estimated at >$2.0 B in US. | ||
Expert Team to | Management has history of >$1B in pharma M&A; Scientific Advisors | |
Execute | are key KOL's in infectious disease, breast surgery, pulmonology (ARDS) | |
ManagementManagement / Founders have invested $26.5 million into the company
CommitmentHave persevered with clinical research in the Covid-19 pandemic
Olympic Motto: "Citius, Altius, Fortius" (Faster, Higher, Stronger)
NASDAQ: CTXR | 3 |
Management
Leonard Mazur, Director and Executive Chairman
- Founder/co-founderof: Genesis, Triax, Akrimax, and others
Myron Holubiak, Director, CEO and President
- Former President of Roche Laboratories, Inc.
Jaime Bartushak, EVP, Chief Financial Officer
- Over 20 years experience in corporate finance, M&A, and strategic planning
Myron Czuczman, M.D., EVP, Chief Medical Officer
- Recent Therapeutic Area Head and Vice President of the Clinical Research and Development Global Lymphoma/CLL Program at Celgene
- Former Chief, Lymphoma/Myeloma service at Roswell Park Comprehensive Cancer Center in Buffalo
- Has published more than 180 peer-reviewed journal articles
Gary Talarico, EVP, Operations
- Has led commercial activities for many corporate expansions and start-ups, including Reliant Pharma and Ventiv Health
Alan Lader, Ph.D, VP, Clinical Operations
- Over 25 years of experience in medical research, former Instructor in Medicine at Harvard Medical School and Brigham and Women's Hospital
Andrew Scott, VP, Business Development
- 20 years of transactional experience in strategic planning, product identification, asset acquisition, and capital markets communication
NASDAQ: CTXR | 4 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Citius Pharmaceuticals Inc. published this content on 21 January 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 January 2021 18:45:05 UTC